Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Beast mode 2.0
https://www.virgingalactic.com
$SPCE
Someone on the Board of directors with some serious voting power slammed the meeting down.
I think this is great. HEPA is holding back on a wide array of updates on multiple indications. If you think about this it's the best thing that could of happened.
Again Those who don't know the most basic stuff, like the difference between authorized shares and issued shares, really shouldn't be trading stocks at all, but then they won't be around for very long, so!
I will buy one more large chunk under 2.30 Monday if the opportunity presents itself. Look at the 3 month chart on ATOS and HEPA is looking like the ATOS chart three months ago. Hovering mid 1.40's range and boom had a market cap of under 200 million and hit a billion before the a pullback Friday at the close.
Also this is key! Most importantly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64 million shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64 million shares at those offerings, there were 12 million shares out, with 3 million in the public float. So, direct holders had ~9 million shares of that, and tutes got 64 million shares at the offerings, which possibly left ~3 million shares for retail then. Also the chart is golden for upward continuation for the foreseeable future IMO going int0 2022 & beyond.
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Lots of catalysts on tap!
Marching forward.
$MNMD
HEPA chart similar patterns forming to where ATOS was 3 months ago. My friend who is a chart wizard just pointed this out to me.
3 Month Chart on ATOS 120 million shares outstanding and 137 Million in cash Billion dollar market cap up 348% in 3 months.
3 month Low 1.48
3 month high High 9.70
HEPA I believe we see similar price movement through 2021 with Hepa similar move to ATOS
HEPA 120 million in cash 76 million shares outstanding most accounted for by institutions & insiders!
170 Million market cap
$ATOS
$HEPA
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Breakout in progress shorty in a hot mess!
$SPCE
Added 75 shares today core position!
$MSTR
Thanks for the concern this is where I got my info!
According to yahoo finance PDSB is up 695%+ 52 week change at the moment.
All my shares are free and clear house money now.
https://finance.yahoo.com/quote/PDSB/key-statistics?p=PDSB
$PDSB
Off to play a few rounds of golf hold down the fort gentlemen. These MM are In deep poop. This might be a GameStop type situation where a few hedgies go bankrupt from there illegal games of naked shorting of HEPA!
Remember there are only a few million shares floating around 90-95% have been bought by institutions and insiders from the last 2 offerings this year! Again 170 million market cap 120 million in cash burning under 5 million a quarter! I really believe we see a billion dollar plus valuation soon for Hepa! 13.00 a share equals a billion market cap for Hepa! Puts the company in-line with AKRO 1.2 billion market cap and MDGL 1.7 billion market and we have the goods!
https://giphy.com/gifs/dump-part-13AurJL9v5Oo48
$HEPA
Accumulating more to my stash in a few minutes.
Small cap bios with exponential growth are going to be in focus for investors. Hepa at these levels is one of my top picks.
HEPA double digits are coming!
It’s peers AKRO and MDGL have 1.2 billion and 1.7 billion market caps with no where near the safety of CRV431 which is what the FDA is looking for first and foremost in the Nash space and top line data is great on the 75mg 225mg remember Hepa has AI power platform to help it obtain the right clinical trial outcomes and patient selection to save time and money! Hepa only burns under 5 million a quarter and has 120 million in the bank and a market cap of 167 million. Don’t forget about Hobbs the new CMO a high level executive for 17 years at novo nordisk a 190 billion dollar company who came on to HEPA this year to take charge of all clinical trials.
I just added a fat chunk under 2.30 while these clown MM where playing games this 10x soon and a possible 100x in the next 4-5 years. Time to show their ladies some love and attention while they stuff there mouths with sausages where the guy who said where going under 2.00 another circus clown!!! Time to pay the piper one of the great squeezes about to transpire book it! Millions will be made with a decent stash in my opinion! Just like PDSB and NVAX 7 figure winners for me! Opportunity of a lifetime with Hepa at these levels!
$HEPA
The science here has mega blockbuster potential, in terms of the wide array of indications for which CRV431 holds great promise, and the degree to which it looks like it can treat them, many of which have worldwide annual treatment markets in the many billions, and some in the tens of billions.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Most importantly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64 million shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64 million shares at those offerings, there were 12 million shares out, with 3 million in the public float. So, direct holders had ~9 million shares of that, and tutes got 64 million shares at the offerings, which possibly left ~3 million shares for retail then. Also the chart just reversed. Bought a multi million dollar house in maui from my PDSB still riding a ton of shares on the house now. Looking for similar type returns with HEPA. Company has 120 million in the bank company is burning under 5 million a quarter!
Hepion Pharmaceuticals to be Added to the Russell Microcap(R) Index
This can double or triple in a blink of an eye. It’s coming! MM Im coming after that ass! MM These tootles legless buffoons trying way to hard this morning :) Lets squeeze them and spank them real good!! what a bunch of clowns scum of the earth!!
https://giphy.com/gifs/dump-part-13AurJL9v5Oo48
$HEPA
Page S321
https://easl.eu/wp-content/uploads/2021/06/EASL_2021_-Version-1_new.pdf
Poster Presentation:
Human Precision Cut Liver Slices as a model of Alcohol-related Liver Disease: recapitulating disease progression in a dish.
We describe the development of an immunocompetent ex-vivo humanmodel of ALD based on the culture of Precision Cut Liver Slices (PCLS)and their direct application for the assessment of the therapeutic effects of the cyclophilin inhibitor, CRV431( Journal of Hepatolog 2021).
Conclusion:In summary, we have developed a versatile immuno-competent platform which can reliably recapitulate the clinical features of ALD and have shown that it can be effectively employed to assess the efficacy of novel immunomodulatory and anti-fibrotic therapeutic agents
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish. HEPA has the safest NASH molecule in the clinic today by far & its pill versus vaccines by its peers is showing optimal efficacy on small doses of 75mg most anti fibrotic drug in the clinic today. Most importantly its very very safe that's what the FDA is looking for with no FDA approved drugs for NASH
Phase 2A data on CRV431 225mg between next week and the end of June. Last year they announced the day before the conference they where presenting. And as well as inclusion into Russell index!!
Phase CRV431 2A preliminary conclusions:
1.Reduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjects.
2.CRV431 in NASH Phase 2a Preliminary ConclusionsReduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjectsCRV431 concentration predicts reductions in serum alanine transaminase.
3.Trial Simulations suggest greater expected efficacy at 150 mg and 225 mg dose levels.
4.Bioinformatics with AI-POWR?reveal significant interactions with collagen regulating genes.
5.Confirmation of these effects will be fully evaluated using the 225 mg cohort and the final genomic, lipidomic, and biomarker data for a full simulation of the Phase 2b Trial.
AI-POWR™ Confers Strategic Advantages from Clinical Trials to Commercialization:
A.Novel drug target selection
B.Biomarker selection and validation
C.Patient selection (-responder analysis)
De-risk clinical trials
D.Improve drug development efficiency with cost savings
HEPA molecule CRV431 for NASH is safer than MDGL & AKRO & HEPA Efficacy looks next level. These 2 companies MDGL & AKRO are both Billion dollar plus companies look for HEPA market cap to grow exponentially.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
About to go. Get ready!!
https://giphy.com/gifs/pitchperfect-pitch-perfect-2-laUY2MuoktHPy
$HEPA
HEPA Just the beginning.
Gaining strength.
Breakout on the horizon!
The Big short about to become the big looser!
Billion dollar plus market cap in the making in line with it's peers AKRO & MDGL.
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 167 Million market cap 120 million in cash burning under 5 million a quarter.
A $13.00 price per share puts HEPA a Billion dollar market cap valuation something to think about!
Calm before the storm MM shortie crew are going to get the sausages stufffed down deep!
https://giphy.com/gifs/dump-part-13AurJL9v5Oo48
$HEPA
Dirty Market Makers scoundrels power to people I got vendetta for that cheddar. I'm going after that assss I'm taking whats mine do you hear me you clowns stuffing your fat faces with sausages. This is going to be one of the biggest squeezes in history after these fraudsters have been illegal shorting this stock for months with millions of fake shares . Time to pay the pipper!
When you see these monkeys throw a big chunk of shares on the ask you steal it from them the squeeze will be legendary these losers will be out of work soon!
This is the most undervalued small cap bio stock on planet earth.
Hepa is a multi billion dollar market cap in the making! CRV431 is the safest & most antifibrotic molecule in the clinic today for NASH
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Most importantly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64 million shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64 million shares at those offerings, there were 12 million shares out, with 3 million in the public float. So, direct holders had ~9 million shares of that, and tutes got 64 million shares at the offerings, which possibly left ~3 million shares for retail then. Also the chart just reversed. Bought a multi million dollar house in maui from my PDSB still riding a ton of shares on the house now. Looking for similar type returns with HEPA. Company has 120 million in the bank burning under 5 million a quarter!
This can double or triple in a blink of an eye. It’s coming! MM Im coming after that ass!
$HEPA
Stair stepping into the stock hall of fame!
Don’t sleep on it.
Quiet name waking up solid base built last 3 months.
Hepa is a wealth creator in the making opportunity of a lifetime. I find one or two of these small bio caps a year this is one of them that has unlimited growth potential.
Billion dollar plus company in the making. Nash is a huge market no approved drugs to date!
Hepa has the safest and most anti fibrotic molecule in the clinic today. And the other possibilities for this company is mind boggling.
Well funded with a seasoned management team Hobbs left nova nordisk a 190 billion dollar company with a high level position for the past 17 years to take over as Hepa new CMO chief medical officer this year!
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
MM borrowed a lot today.. time for them to be squeezed and spanked bigly!!
$HEPA
Timing is everything in this game!
I see the angles before their being played!
My spider senses senses tell me 100k shares can make you a multi millionaire by 2024 you also maximize profits by holding 2 years! AKRO & MDLG are Nash peers trading between 1-2 billion each. Hepa CRV431 is after and works more optimally & the company is laying out the foundation for w wide array of indications.
Hepa burning under 5 million a quarter with 115-120 million in the bank. Hepa market cap is 160 million Hepa team has more experience in the Cyclophilin area than any team in the world. The ceo brought a blockbuster drug to FDA approval with his last company.
Resistance at 2.20 and 2.30!
Ready to Go LONG. .....ITS A BULL FLAG ....The HANDLE on the CUP is Complete !!!!!!!!!!!!!!!!!
HRPA CRV431 molecule in action
Biotech Value equals HEPA
Breakout imminent don't sleep on it.
3 month cup we have been waiting out is finished. The handle retraces 1/3 and …. BOOM!
$HEPA
Got my fill this am.
Wants to go parabolic!
HEPA Reeling in the blue fin tuna.
https://giphy.com/gifs/OutsideTV-1iNbV9GcurOSOuqlvH
First we break 2.20 & then 2.30 Then its game time!
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
Quiet name.
Waking up.
HEPA potential wealth creator will make people lots of people money buying at these bargain basement price levels IMO.
$HEPA
Hepa three month cup we have been waiting out is finished. The handle retraces 1/3 and …. KABOOM!
Hepa competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach $84 Billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Hobbs leaves a 183 Billion dollar company with the one the biggest pharmaceutical companies with a very cushy job and you can damn well bet that he didn't leave his VP/CMO position thto take lead CMO at HEPA think about it! He's not going to Hepa to play %$%& tiddlywinks
Most importantly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then. Also the chart just reversed. Bought a multi million dollar house in maui from my PDSB still riding a ton of shares on the house now. Looking for similar type returns with HEPA.
There are no shares available the MM are swapping spit with one another's accounts trying to pry loose a few shares from weak pathetic and uneducated retail types. HEPA stock can double or triple in a blink of an eye just have the vision and patience and balls of fortitude. Diamond hands laser eyed Hepa Bulls long & strong! This small biotech 160 million market cap has potential to reach tens of billions of dollars buy hold and forget about it and lock your shares up. Looking for similar or greater ROI on HEPA than with NVAX & PDSB long term.
Adding this morning right at the open!
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash burning under 5 million a quarter
https://easl.eu/event/the-international-liver-congress-2021/
$HEPA
PDSB one of the top performing stocks of 2021 up 700%
Let it do its thing it can take off on a moments notice & run like hell.
$PDSB
Easy breezy my friend.
One of my core holdings!
$SPCE
Hepa competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach $84 Billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Hobbs leaves a 183 Billion dollar company with the one the biggest pharmaceutical companies with a very cushy job and you can damn well bet that he didn't leave his VP/CMO position thto take lead CMO at HEPA think about it! He's not going to Hepa to play %$%& tiddlywinks
Lastly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then. Also the chart just reversed. Bought a multi million dollar house in maui from my PDSB still riding a ton of shares on the house now. Looking for similar type returns with HEPA.
[color=red]There are no shares available the MM are swapping spit with one another's accounts trying to pry loose a few shares from weak pathetic and uneducated retail types. HEPA stock can double or triple in a blink of an eye just have the vision and patience and balls of fortitude. Diamond hands laser eyed Hepa Bulls long & strong! This small biotech 160 million market cap has potential to reach tens of billions of dollars buy hold and forget about it and lock your shares up. Looking for similar or greater ROI on HEPA than with NVAX & PDSB long term[./color]
Adding this morning right at the open!
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
https://easl.eu/event/the-international-liver-congress-2021/
$HEPA
Added to my stash yesterday this china mining news is way overblown. I feel I hear the same story rehashed twice a year for the last 3 years.
MSTR 100k Bitcoins HODL
Bitcoin is a swarm of cyber hornets serving the goddess of wisdom, feeding on the fire of truth, exponentially growing ever smarter, faster, and stronger behind a wall of encrypted energy.
Michael Saylor
MSTR
Looks great. I have been adding the last 2 days heavy.
HEPA is my top small cap bio pick. Looking for a big move in second half of 2021 & 2022 Like holding for 2 years to maximize profits.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Great close killing it on the options and holding my core stash.
$SPCE
Yes & to answer your question on the PM not me.
Brazil news coming
$PDSB
Added a thick chunk today thanks for spreading the data.
Love reeling in the blue fin tuna while the market makers swap bodily fluids with one another! what a bunch of donkeys!!!
HEPA molecule CRV431 for NASH is safer than MDGL & AKRO & HEPA Efficacy looks next level. These 2 companies MDGL & AKRO are both Billion dollar plus companies look for HEPA market cap to grow exponentially.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Thats cool have been buying since the .30 range & will buy more at these levels.
$MNMD
After the February offering, that showed Cerrone's stake going from 5.4million shares to 10.2 million shares and Garlikov's from 3.4 million shares to 6.6 million shares
90-95% of all shares are being held by institutions & insiders after the 120 million was raised in the last year from the last 2 offerings.
There are very few shares floating around MM have been manipulating the stock in 2021 and trying to steal every single share from
uneducated investors who have no patients & vision.
This was all planned out a long time ago...
Making millions is possible with a decent stash of HEPA shares. I Hit the jack pot on multiple stocks in the last 18 months most notably NVAX & PDSB still own 125k shares of PDSB free and clear and own a ton of HEPA shares & will load more in methodical buying over many accounts some GTC some not these toothless buffoons don't know whats about to hit them hard. HEPA is next runner with over 100x ROI from current levels. I see the angles before they are being played. I also have dozens of people invested and multiple more buying thick stashes this week including family offices who bought last week. These MM are about to get their clock cleaned.
Key data points:
HEPA CRV431 is the safest & most anti fibrotic molecule in the clinic today! for NASH!
"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH
NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.
In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
$HEPA
Lots of announcements from companies today about presentations at the upcoming EASL conference.
Hepion will almost certainly be presenting something there, too.
If so, we'll see whether they announce it tomorrow morning, or do like they did with the EASL presentation last August, with the PR on the same day as the presentation of CRV431 P1 results.
HEPA CRV431 is the most optimal antifibrotic drug in the clinic. The wide array of applications this drug can be used for can make HEPA 50- 100 Billion dollar company in the next 5 year years. No FDA approved drugs for NASH
The International Liver Congress 2021 will begin on
Wednesday June 23 and ends on Saturday, June 26 2021
https://easl.eu/event/the-international-liver-congress-2021/
NASH is 35 Billion dollar market that will near 100 Billion next 5-10 years.
Hepion - Page S321
https://easl.eu/wp-content/uploads/2021/06/EASL_2021_-Version-1_new.pdf
Background and aims:The canonical experimental models (i.e. cellculture and rodents) for the study of Alcohol-related Liver Diseases(ALD) present limitations which impede the advancement of noveltherapies, particularly the difficulty in recapitulating the spectrum of pathological manifestations associated with the development/pro-gression of ALD in humans including steatosis, inflammation, hepatotoxicity, fibrosis and cirrhosis. The need to overcome this barrier to drug development underpins the current study. We describe the development of an immunocompetent ex-vivo humanmodel of ALD based on the culture of Precision Cut Liver Slices (PCLS)and their direct application for the assessment of the the Therapeutic effects of the cyclophilin inhibitor, CRV431.Method:Tumour-free liver specimens (‘healthy’or cirrhotic) we recollected from patients (n = 22) undergoing resection of livermetastasis. PCLS were made from the resected tissue, cultured forup to 5 days, and exposed to hepatotoxic insults: ethanol 50–250 mM, oleic/linoleic acids 0.1 mM, and LPS 10 µg/ml. The thera-peutic effects of 5 µM CRV431 were studied for the duration of theculture. Viability and cell death were evaluated by histology,cytokeratin 18 release, and ATP content. Steatosis was evaluated byOil-Red-O staining. Fibrosis was measured by gene expression,secretion and histology. Inflammatory cytokines were quantified byluminex. Mitochondrial fitness was evaluated by functional andmorphological assays.Results:The exposure of PCLS to ethanol for increasing time periods(up to 5 days) could mimic the clinical features of ALD. Early ethanolexposure was characterised by low overall cell death but increasedmitochondrial alterations. The addition of fatty acids and an acuteinflammatory hit (LPS) promoted steatohepatitis, inflammatorycytokine production and fibrosis. The cirrhotic PCLS were used toinvestigate tissue architecture and fibrotic processes in the context oflate stage chronic disease. PCLS treated with CRV431 maintainedgood viability, mitochondrial function, and low apoptosis over theculture duration. CRV431 also tempered inflammation in thepresence of LPS and induced a dramatic decrease in gene expressionand deposition of Collagen and Timp-1.Conclusion:In summary, we have developed a versatile immuno-competent platform which can reliably recapitulate the clinicalfeatures of ALD and have shown that it can be effectivelyemployed toassess the efficacy of novel immunomodulatory and anti-fibrotictherapeutic agents.PO-2331Past hospital contacts due to alcohol do not predict fibrosis stagein alcohol-related liver disease. A study of alcohol diagnoses andmorbidity in 18 years leading up to biopsy-proven liver fibrosis in462 patientsDitlev Rasmussen1, Maria Kjærgaard1, Katrine Prier Lindvig1,Mads Israelsen1, Kathrine Thorhauge1, Nikkolaj Christian Torp1,Stine Johansen1, Sönke Detlefsen2, Aleksander Krag1, Maja Thiele1.1Odense University Hospital, Departnemt of Gastroenterology andHepatology;2Odense University Hospital, Department of Pathology,DenmarkEmail: ditlev.nytoft.rasmussen@regionh.dk.Background and aims:Decompensated alcohol-related liver diseaseis preceded by several years of excessive drinking. Hospital contactsforalcohol problems are potential opportunities forearly detection ofcirrhosis. We aimed to investigate whether patients with biopsy-proven severe fibrosis and cirrhosis had more past hospital contactsdue to alcohol than alcohol-overusing patients with significant or minimal fibrosis.
Phase 2A data on CRV431 225mg between next week and the end of June. Last year they announced the day before the conference they where presenting. And as well as inclusion into Russell index!!
Phase CRV431 2A preliminary conclusions:
1.Reduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjects.
2.CRV431 in NASH Phase 2a Preliminary ConclusionsReduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjectsCRV431 concentration predicts reductions in serum alanine transaminase.
3.Trial Simulations suggest greater expected efficacy at 150 mg and 225 mg dose levels.
4.Bioinformatics with AI-POWR?reveal significant interactions with collagen regulating genes.
5.Confirmation of these effects will be fully evaluated using the 225 mg cohort and the final genomic, lipidomic, and biomarker data for a full simulation of the Phase 2b Trial.
AI-POWR™ Confers Strategic Advantages from Clinical Trials to Commercialization:
A.Novel drug target selection
B.Biomarker selection and validation
C.Patient selection (-responder analysis)
De-risk clinical trials
D.Improve drug development efficiency with cost savings
HEPA molecule CRV431 for NASH is safer than MDGL & AKRO & HEPA Efficacy looks next level. These 2 companies MDGL & AKRO are both Billion dollar plus companies look for HEPA market cap to grow exponentially.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
$HEPA
Just reeled in another 5k lot I’m thirsty and hungry!
$PDSB
Hepa accumulating here!
Market makers are swapping bodily liquids with one another while I have my nets out sponging up small lots with precision laser like focus methodically across half dozen brokerage accounts. All day long reeling in the blue fin tunas.
Most undervalued biotech on the market under 200 million. Know an opportunity when it presents itself and seize the moment.
Hepa down 15% for the year if you can see the angles before they are being played you can make a small fortune here 500%~1000% upside from here sooner than later. Same thing was happening with PDSB and then kaboom!!
$HEPA
Wants to go higher next leg up on tap.
https://mindmed.co/
$MNMD
HEPA market cap should be north of a billion dollars superior safety data & top line data compared to MDGL & AKRO
Nash Companies in Phase 2 & 3 Trials by companies in the space:
$AKRO Therapeutics 1.1 Billion Marketcap 240 Million in cash.
$MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash.
$HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash. Burning under 5 million a quarter.
lots of catalyst and hammers in the HEPA pipeline.
of 2019. On June 10th, we were looking at that 8.89 you see in the picture. The high in June of 2019 was 16.49, on the 17th, intraday. We can talk about variables, changes, dynamics, developments, or anything under the sun, until the f'n cows come home, but the way this stuff works is that the 8.89 is etched somewhere, and the 16.49, too... Everything was drawn up long ago, and if you can't see that it's all choreographed, you're not looking, because there is absolutely nothing more that could be done to make it any more obvious. If you believe in randomness, you're in the wrong place. By the way, some competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions
June 27th is the two-year anniversary of the IND filing for CRV431 in NASH
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
Wealth Creator only piss poor fruity clowns would short this stock.
PDSB up 735% year to date! and still climbing.
$PDSB
Nice DD
Hepion Pharmaceuticals Inc. [HEPA] stock Resumed by ROTH Capital analyst, price target now $14.00
Nash Companies in Phase 2 & 3 Trials by companies in the space:
$AKRO Therapeutics 1.1 Billion Marketcap 240 Million in cash.
$MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash.
$HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash. Burning under 5 million a quarter.
In just 28 days at the low dose 75mg, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
HEPA 225mg Data between monday morning & next week.
Phase CRV431 2A preliminary conclusions:
1.Reduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjects.
2.CRV431 in NASH Phase 2a Preliminary ConclusionsReduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjectsCRV431 concentration predicts reductions in serum alanine transaminase.
3.Trial Simulations suggest greater expected efficacy at 150 mg and 225 mg dose levels.
4.Bioinformatics with AI-POWR?reveal significant interactions with collagen regulating genes.
5.Confirmation of these effects will be fully evaluated using the 225 mg cohort and the final genomic, lipidomic, and biomarker data for a full simulation of the Phase 2b Trial.
$HEPA